tissue engineering

Adiana Research and Development is a company focused on tissue and organ regeneration and tissue engineering. It develops a bioactive molecular scaffold created through two-photon laser-initiated polymerization and 3D printing, using extracellular matrix materials derived from early invertebrates. The company is led by Director and Founder Dr. William Lafayette Mondy, who also serves as President and Chief Technology Officer.

3D printingBio-CAD designtwo-photon laser-initiated polymerization

ArthroNovus was founded in 2025 to pursue development of structural autologous solutions to osteoarthritis. In partnership with experts at University Hospitals and Case Western Reserve University, the company is developing a new therapeutic treatment for focal cartilage defects, aiming to create Anatomically Competent replacement parts sourced from the patient's own cells that preserve and heal native anatomy.

cell biologymechanical conditioning of tissues

Aspect Biosystems is a Canadian biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how some of the most elusive diseases are treated. Its full-stack tissue therapeutic platform integrates AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials to build allogeneic tissue therapeutics designed to replace, repair, or supplement biological function in the body.

biomanufacturingbioprintingcomputational designlab automationmachine learningmicrofluidic printheadsregenerative medicine

0 Our mission To improve the standard of care for treatment of gastrointestinal bleeding and protection of the mucosa in endoscopy procedures. We are developing GastroShield, an advanced biocompatible material for effective management of gastrointestinal bleeding and shielding of high-risk lesions. Instant hemostasis Activates immediately upon application. Durable Barrier remains adhered in place during the healing process. Protective Barrier Strong and flexible shield provides effective bleed management. Transparent Preserves visualization of the lesion. The Problem:GI hemorrhage alone results in +500,000 hospital admissions +2 MILLION hospital days $5 BILLION in direct costs 11,000 in-hospital deaths. Despite advances in endoscopy, controlling GI bleeding and protecting large lesions remains challenging. Unreliable hemostasis Powder hemostats can cloud visualization, clog catheters.

hydrogel systems developmentmaterials science research

Bio Organs is a biotechnology start-up developing patient-specific, vascularized cardiac tissue patches to help restore heart function after heart attack and delay progress toward heart failure. The patches are made using patient-specific iPSC-derived cardiovascular cells and can connect to the patient's blood supply immediately at implantation while triggering a reduced immune response.

3D bioprintingpersonalized iPSC-derived cell therapies

BioTissue, a double spin-off of the Charité University Hospital in Berlin and the University Hospital in Freiburg, works in regenerative medicine and tissue engineering. Its technology platform offers implants applicable through minimally invasive surgical procedures to harness the body's own regenerative potential, with orthobiological solutions for cartilage defects.

guided tissue regenerationregenerative medicineresearch and development

EVOMEDIS is a research and development stage life science company based in the ZWT Graz, established as a spinoff from parent company QRSKIN. It develops new therapies for wound treatment, especially chronic wounds and deep second-degree burn wounds, aiming to shift the paradigm from wound care to wound healing. Its products include EVOSens, EVOCellic and EVOSource.

cell-based therapy developmentproduct repositioning and IP generationwound healing R&Dwound monitoring sensor development

Fluicell is a life science company founded in 2012 in Mölndal, Sweden, pioneering high-precision tissue engineering and open volume microfluidics. Its Nexocyte™ tissue therapeutics platform, based on high-resolution single-cell bioprinting technology Biopixlar, is used to develop transplantable tissues for regenerative medicine and tissue models for drug screening, with a first goal of developing transplantable tissues to cure type 1 diabetes.

drug screeningopen volume microfluidicsregenerative medicinesingle-cell bioprinting

FluidForm Bio builds living human tissue for better treatment of disease using its patented FRESH 3D bioprinting platform, which builds tissue using cells, proteins, and nothing else. Founded in 2018, the company integrates innovations in 3D printing, computational and synthetic biology, AI and machine learning, and advanced materials science to develop human tissue. Its FRESH 3D bioprinting enables implantable tissue that promotes dense vascularization, with potential application toward a minimally invasive cure for type 1 diabetes.

3D bioprintingadvanced materials scienceAI and Machine Learningbiomanufacturingcomputational and synthetic biologyFRESH 3D bioprinting

Fortuna Therapeutics is a biotechnology and biopharmaceutical company focused on endocrine regenerative cellular and engineered endocrine tissue therapies for parathyroid, thyroid and adrenal disease-related endocrine dysfunctions. Its mission is to resolve human endocrine gland dysfunction and life-long dependence on exogenous synthetic hormone replacement therapy. The company utilizes stem cell technology, microgravity properties, in-space endocrine organoid growth, tissue engineering, and biopharmaceutic manufacturing in low-earth orbit for terrestria

biopharmaceutic manufacturing in low-earth orbitin-space endocrine organoid growthstem cell technology